Sequana Medical Enhances Share Structure with New Issuance

Sequana Medical Enhances Share Structure with New Issuance

Sequana Medical, a leader in innovative treatments, reveals an update in its share capital and shares.

Recently, Sequana Medical NV (Euronext Brussels: SEQUA) announced a significant development regarding its share capital. The company, recognized as a pioneer in the treatment of drug-resistant fluid overload associated with liver disease, heart failure, and cancer, shared that it has successfully completed a subscription for new shares by GEM Global Yield LLC SCS. This subscription resulted in an increase of the Company’s capital to EUR 5,535,546.75. In total, the number of issued and outstanding shares rose from 52,867,073 to 53,428,572 ordinary shares. The new shares were issued at an attractive price of EUR 0.9425 each to GEM.

Details of the Capital Increase

This capital increase reflects the fulfillment of a subscription request made to GEM, based on a facility agreement established on March 17, 2025. The company’s board of directors had previously approved this move under the framework of authorized capital on April 8, 2025. This strategic decision ensures that Sequana Medical is well-equipped to continue its groundbreaking work, particularly in addressing fluid overload in patients suffering from various severe conditions.

Subscription Rights and Share Options

The total number of outstanding subscription rights now stands at 3,899,576. If these rights are exercised, holders could subscribe to 5,066,304 new shares with voting rights. Here’s how they break down:

• Executive Share Options: Up to 261,895 shares may be issued upon the exercise of 90,780 outstanding share options for staff and consultants.
• 2018 Share Options: Up to 687,784 shares from share options that can be exercised by directors and employees, each yielding one new share.
• 2021 Share Options: Holders can claim up to 188,370 new shares through their share options under this plan.
• 2023 Share Options: With this framework, up to 1,000,000 new shares could potentially be issued.
• Bootstrap Warrants: Up to 302,804 shares may be issued to Bootstrap Europe S.C.SP.
• Kreos Warrants: Potentially, up to 1,567,819 shares can be claimed upon exercising 875,000 outstanding warrants.
• 2023 Investor Warrants: Up to 1,057,632 shares are available through subscription rights under the private placement plan.

About Sequana Medical's Innovative Treatments

Sequana Medical NV is at the forefront of addressing fluid overload, a pressing clinical issue that greatly affects patients with liver disease, heart failure, and cancer. Traditional treatments, primarily diuretics, often prove ineffective for many patients, leading to severe complications and low quality of life. The company aims to provide viable alternatives for this substantial patient cohort. Their proprietary platforms, alfapump® and DSR®, are designed to alleviate diuretic-resistant fluid overload. These groundbreaking treatments intend to enhance both clinical outcomes and the quality of life for patients while potentially lowering healthcare costs.

In a pivotal stride, Sequana Medical received US FDA approval for the alfapump System, which targets recurrent ascites due to liver cirrhosis. Following its FDA Breakthrough Device Designation in 2019, the company looks forward to augmenting its presence in the US market beginning in Q3 2025, aiming for liver transplant centers.

Sequana’s recent studies, particularly the RED DESERT and SAHARA trials, have showcased the effectiveness of DSR in breaking the cycle of cardiorenal syndrome, with impressive patient outcomes reported. The results indicate significant improvements in diuretic response, substantially reducing the reliance on loop diuretics.

Contact Information:
For further inquiries, please reach out to Sequana Medical's Investor Relations via email at IR@sequanamedical.com or call +32 9 292 8065.

Frequently Asked Questions

What significant change did Sequana Medical announce?

Sequana Medical announced an increase in its share capital and the number of outstanding shares due to a subscription by GEM Global Yield LLC SCS.

What was the new share capital amount after the change?

The new share capital amount increased to EUR 5,535,546.75.

How many new shares were issued to GEM?

A total of 561,499 new shares were issued to GEM.

What are some of the leading products offered by Sequana Medical?

Sequana Medical offers alfapump® and DSR®, which are targeted at treating diuretic-resistant fluid overload in patients.

How can I contact Sequana Medical for more information?

You can contact Sequana Medical's Investor Relations at IR@sequanamedical.com or by phone at +32 9 292 8065.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.